Clinical trials of the Institute of Cell Therapy

One of the priority areas of the Institute of Cell Therapy activity is the development of new methods of treatment of socially important diseases with the use of stem cells. To date, the Institute of Cell Therapy has developed methods for cell therapy of pathological conditions such as

  • 1) Violation of contractile function of the heart
  • 2) Ischemic cardiomyopathy
  • 3) Diseases of the peripheral arteries of the lower extremities
  • 4) Pancreatic necrosis
  • 5) Diabetic peripheral neuropathy
  • 6) Peripheral artery lesions in patients with diabetes mellitus
  • 7) Trophic ulcers of the lower extremities
  • 8) Cirrhosis of the liver
  • 9) Viral hepatitis
  • 10) Osteoarthrosis
  • 11) Keratitis of infectious and neurotrophic etiology

The Institute of Cell Therapy also possesses exclusive anti-aging techniques using placenta extract and stem cells.

According to national and international legislation, new treatments are approved by the Coordination Center for Transplantation of Organs, Tissues and Cells of the Ministry of Health of Ukraine before being approved by the Ministry of Health of Ukraine.

In 2012, the Ministry of Health of Ukraine, after 5 years of clinical trials, officially approved the treatments for critical ischemia of the lower extremities and acute pancreatitis / pancreatic necrosis, developed by the Institute of Cell Therapy, based on the use of cord blood stem cells. The conducted clinical studies have proved their safety and high efficiency. The Institute of Cell Therapy method for acute pancreatitis / pancreatic necrosis treatment has also attracted the attention of the international medical community, and clinical research data is published on the website of a leading international organization, promoting awareness on this biological material in the world, that is the Parents’ Guide to Cord Blood Foundation

Currently, the Institute of Cell Therapy has completed 4 more clinical trials on the treatment of such diseases as

  • 1) Impairment of contractile function of the heart (umbilical cord stem cells were used)
  • 2) Diseases of the peripheral arteries of the lower extremities (multipotent mesenchymal stromal cells of adipose tissue and bone marrow were used)
  • 3) Keratitis of infectious and neurotrophic etiology (amniotic membrane of placenta was used)
  • 4) Pancreatic necrosis (umbilical cord stem cells and umbilical cord tissue were used).

Clinical trials are ongoing to treat the following diseases:

  • Chronic hepatitis and liver cirrhosis of the viral etiology (use of mesenchymal stromal cells of the placenta)
  • Ischemic cardiomyopathy (use of myocardial stem cells, bone marrow, placenta, adipose tissue and their combinations)
  • Diabetic peripheral neuropathy (cryopreserved human umbilical cord blood cells, cryopreserved multipotent mesenchymal stromal cells isolated from the human placenta and cryopreserved human amniotic membrane are used both separately and in combinations)
  • Peripheral lesions of the arteries in patients with diabetes mellitus (use of cryopreserved human nucleated umbilical cord cells, cryopreserved multipotent mesenchymal stromal cells, isolated from the human placenta and cryopreserved amniotic membranes)
  • Trophic ulcers of the lower extremities (the use of cryopreserved nucleated human umbilical cord cells, cryopreserved multipotent mesenchymal stromal cells, isolated from the human placenta and cryopreserved human amniotic membrane separately and in combinations)
  • Osteoarthrosis (use of bone marrow stem cells and placenta).
Feedback
Call or email us for more information
Contact us